Human rhinoviruses (HRVs), the viruses predominantly associated with the common cold, are highly prevalent in both immunocompetent and immunocompromised individuals. Prior to the development of sensitive molecular viral detection assays, infl uenza, respiratory syncytial virus, and parainfl uenza virus were the most common and most concerning respiratory viral pathogens detected in hematopoietic cell transplant (HCT) recipients [ 1 ] . Due to the development of polymerase chain reaction (PCR) assays for viral detection, HRVs are now known to be the most common viruses detected from respiratory specimens in HCT recipients and can account for 25-40% of cases of viral respiratory infections in these patients [ 2 -4 ] (Figure 32-1 ). Due to their high prevalence and their ability to cause progressive infection, HRVs are also a signifi cant cause of lower respiratory tract infection (LRTI) in HCT recipients (Table  32- 1 ) . HRV infection is also common in solid organ transplant (SOT) recipients , although the incidence is not known among SOT recipients as a whole. In lung transplant recipients , data from older retrospective and prospective studies suggests an incidence of 35-55% among patients with positive respiratory samples [ 5 -7 ] (Figure 32-2 ) . In a recent prospective surveillance study of 112 lung transplant recipients, HRVs represented 62% of all positive samples [ 8 ] . Among symptomatic lung transplant recipients, HRV represented 34% of all respiratory viruses detected [ 9 ] .
HRVs are members of the Picornaviridae family and are classifi ed into three species, HRV-A, HRV-B, and HRV-C, based on similarity in genome organization, capsid features, and conserved sequences [ 10 ] . The total number of genotypes continues to grow as new genotypes are characterized; currently at least 160 unique genotypes are described. Due to poor growth in traditional viral culture models, HRV-C was only recognized after the development of molecular diagnostic techniques. Thus, HRV-C is not a novel species, but rather one that has been circulating unnoticed due to lack of an appropriate diagnostic assay. There are several biologic characteristics of HRV-C that differentiate the species from HRV-A and HRV-B. HRV-A and HRV-B both use ICAM-1 or LDLR for cell attachment and entry, whereas it appears that HRV-C may utilize a distinct receptor, cadherin-related family member 3, that is associated with asthma susceptibility [ 11 , 12 ] . Additionally, HRV-C species are stable at higher temperatures and readily infect upper and lower airways, whereas HRV-A and HRV-B species tend to be more limited to the sinuses and upper airways [ 13 , 14 ] . These biologic characteristics are thought to play a role in variations in clinical outcomes observed among the different species.
Clinical Characteristics
Most immunocompetent patients with HRV present with an afebrile, self-limited syndrome characterized by rhinorrhea, nasal congestion, and malaise, and less frequently sore throat, mild cough, and hoarseness [ 15 -19 ] . HRV may also be associated with exacerbations of sinusitis, chronic bronchitis, and asthma, and with lower respiratory tract syndromes and atypical pneumonias in otherwise healthy people, including the young and the elderly [ 20 , 21 ] . The specifi c mechanisms by which HRVs produce lung diseases are not well understood. HRVs are also implicated in asthma and chronic obstructive pulmonary disease (COPD) exacerbations, but again the mechanisms are poorly defi ned.
With the widespread availability of PCR diagnostics, data are emerging on the incidence and clinical relevance of HRV infections in immunocompromised patients. Early studies relied on culture to detect HRV, a specifi c but insensitive method because the standard viral culture systems are not optimized for HRV detection, especially HRV-C [ 22 ] . For example, a Fred Hutchinson Cancer Center surveillance study from 1987 to 1992 detected HRVs in 29 specimens, and only one was from a lower respiratory tract specimen [ 2 ] . A prospective 5-year study at MD Anderson Cancer Center cultured specimens specifi cally for HRVs at lower temperatures with roller culture methods, and reported that HRV infections were associated with substantial morbidity and mortality in 7 of 22 (32%) myelosuppressed patients [ 23 ] . In that study, approximately one third of the adult HCT recipients who developed symptomatic HRV infections prior to engraftment had progression of upper respiratory tract symptoms to LRTI, and all cases with pneumonias were fatal. Lung biopsies and autopsies revealed fi ndings consistent with interstitial pneumonitis and/or ARDS, but no in situ evaluation was performed to defi nitively assess HRV infection. Similar reports with evidence of LRTI based on radiographic and BAL fi ndings continue to be noted [ 24 -26 ] , but it remains unknown if pneumonia is a direct cause of viral invasion of the lung tissue or by host responses in the lung. Evidence for in vitro and in vivo replication in lower respiratory tract has been shown in experimental infection, where HRV was isolated from human volunteers after intranasal HRV challenge by in situ hybridization [ 27 ] . The use of RT-PCR continues to provide new information about the frequency of HRV infection. In a study of BAL samples from 77 HCT recipients that were tested using RT-PCR , HRV was detected in six patients (8%), mortality rate was very high (83%) and two of the six patients showed persistent HRV infection. However, all of the HRV-infected patients had signifi cant coinfections and it was not certain whether HRV infection was the direct cause of poor prognosis [ 25 ] . In a small cohort of patients with hematologic malignancy, LRTI was associated with hypoalbuminemia and bacterial copathogens were seen in 25% of patients [ 28 ] .
Recent studies have shown that immunocompromised adults with HRV demonstrated similar hospital admission rates, intensive care unit admissions, and mortality rates as patients with pandemic H1N1 infl uenza [ 29 ] . Several reports have linked HRV infection to severe respiratory failure and even death [ 23 -25 ] . Furthermore, recently presented data suggest that LRTI associated with HRV leads to a mortality rate comparable to that of RSV, infl uenza virus, and PIV [ 30 ] , independent of the presence of co-pathogens. Risk factors for mortality following HRV LRTI included bone marrow stem cell source, oxygen requirement at time of diagnosis, and steroid use ≥1 mg/kg prior to diagnosis [ 30 ] . Other factors that may infl uence clinical severity include the presence of HRV RNA in blood, viral load, and HRV species type; however, no data exist in immunocompromised patients to date. HRV viral RNA was detected in the sera of 30 (12%) of 243 pediatric patients with severe HRV respiratory infection, with HRV-C being the predominant species [ 31 ] . In healthy pediatric patients, increased respiratory viral load has been associated with HRV LRTI and HRVC has been implicated as a more virulent pathogen [ 32 -34 ] . Others, however, have shown lack of correlation between HRV-C and oxygen requirement, length of hospitalizations, and coinfections [ 35 ] . The predominance of HRV-C in HCT recipients has also been described in small studies, with higher rates of pneumonia in patients with HRV-C detected from the upper respiratory tract [ 36 ] . In a small cohort of patients with hematologic malignancies, the rate of LRTI was not different between patients infected with HRV-A, HRV-B, or HRV-C [ 28 ] . The relative risk of HRV-C infection in the immunocompromised population remains unknown, and more research is needed to defi ne the role of strain differences on outcomes.
Detection and diagnosis of respiratory viral infections prior to transplant is a common clinical concern that has until recently only been evaluated in small cohorts for certain viruses [ 37 -40 ] . In a large, prospective surveillance cohort of allogeneic HCT recipients, detection of HRV pretransplant was associated with signifi cantly fewer days alive and out of the hospital, and signifi cantly higher mortality at 100 days posttransplant [ 41 ] . Further, larger prospective studies are needed to determine risk factors for posttransplant complications, the role of viral load and symptom burden at the time of transplantation, and the need to potentially delay transplantation for patients with HRV present prior to transplantation. Ultimately, the issue of viral causality of disease and evaluation of prophylactic and treatment modalities will need to be addressed. The impact of HRV infection prior to SOT is not known.
Like HCT recipients, SOT recipients are exposed to highly immunosuppressive regimens that leave them susceptible to respiratory viral infections. Lung transplant recipients have the added disadvantage of altered lung immunity due to factors such as impaired ciliary clearance, poor cough refl ex, and abnormal lymphatic drainage. These factors can predispose to lower respiratory tract infections. The impact of HRV on outcomes in lung transplant recipients can range from asymptomatic infection to severe disease. In a pooled analysis of all respiratory viruses detected in lung transplant recipients, viruses were detected fi ve times more frequently when respiratory symptoms were present [ 42 ] . A correlation between higher symptom scores and higher rhinovirus load in the upper respiratory tract has been demonstrated, although even asymptomatic patients can have relatively high viral loads [ 43 ] . The relative rate of progression from upper to lower tract disease for HRV specifi cally is not known, although the effect on lung function has been evaluated in aggregate for all respiratory viruses and suggests a decline in forced expiratory volume (FEV1) of −5% to −30% [ 42 ] . For HRV specifi cally, the FEV1 loss was similar to that seen in other respiratory viruses [ 8 ] . The correlation between respiratory viral infections and acute rejection, chronic rejection, and bronchiolitis obliterans syndrome (BOS) remains somewhat unclear, with several confl icting fi ndings when respiratory viruses were evaluated in aggregate [ 6 -8 ] . A recent large cohort of 250 lung transplant recipients, however, showed an independent association between respiratory viral infections (34% HRV) and chronic lung allograft dysfunction in multivariate models [ 9 ] . This association was infl uenced by time, with more of an effect within a shorter period following respiratory infection. Larger, prospective studies investing individual viruses are needed to clearly assess the impact on these outcomes.
Diagnosis
Unlike paramyxoviruses, HRV infection cannot be diagnosed based on characteristic histopathologic changes or changes in cell morphology. In the past, cell culture was used to diagnose HRV infection using multiple cell lines at low temperatures of 33-34 °C, often in rolling tubes. The cell lines utilized for the detection of HRVs may detect enteroviruses; HRV isolates are distinguished from enteroviruses by their lability in acid (loss in viral titer following exposure to a pH of 5). There are no commercially available antigen-detection assays or simple kits for the detection of HRV.
RT-PCR has dramatically improved the ability to both detect and characterize HRVs, with current assays at least two to three times more sensitive than conventional culture methods [ 44 ] . Some PCR assays are able to distinguish between enteroviruses and HRVs instead of the acid lability assays [ 45 ] . Typing of HRVs based on PCR amplifi cation sequence variations in 5′-noncoding region also has been described [ 46 ] . New standardized methods to detect more of the over 100 strains of HRV have now been described [ 47 ] ; however, commercially available multiplex respiratory viral PCR panels contain primer/probe sets that can cross-react between enterovirus and HRV strains. New strains and types of HRV are being detected frequently and more diseases associated with HRV are being described using new and diverse molecular methods.
Treatment Options
There are no approved antivirals for the treatment of HRV infections. Several agents have been evaluated in preclinical and clinical trials for the treatment of HRV infection in immunocompetent hosts, including capsid binding inhibitors, protease inhibitors, and RNA synthesis inhibitors [ 48 ] . None of these agents have been evaluated in immunocompromised hosts. Given the high prevalence and potential severity of HRV infection in this population, there is a great need for drug development and clinical trials for the prevention and treatment of LRTI. Outside of transplant recipients, there is a potential need for intervention in other populations such as patients with asthma or COPD to prevent disease exacerbation [ 49 , 50 ] .
Coronaviruses

Epidemiology
CoVs are a frequent cause of the common cold, but little is known about the role of CoVs in immunocompromised patients [ 51 ] (Table 32 -1 ). Human group 1 (subtypes 229E and NL63) and human group 2 (OC43 and HKU1) CoVs were originally reported as causes of human respiratory illnesses. The availability of more sophisticated diagnostic tools, such as RT-PCR , has facilitated the detection of CoVs in normal and immunocompromised persons. These improved molecular methods of viral discovery facilitated the recent identifi cation of the novel Group 1 and 2 human CoV subtypes-NL63 in 2004 [ 52 ] and HKU1 in 2005 [ 53 ] . A more accurate clinical epidemiology of CoV infection is beginning to emerge. It is now known that all four known subtypes of CoV circulate simultaneously [ 54 ] , and that in addition to the common cold, CoV is associated with upper respiratory tract infection and LRTI in persons with and without underlying conditions [ 55 , 56 ] . In lung transplant recipients, CoVs appear to be the second most common respiratory viruses after picornaviruses with a detection rate of 13-27% of positive samples [ 5 -7 ] (Figure 32-2 ) . In a prospective surveillance cohort of lung transplant recipients, coronaviruses were detected in 13% of all positive samples, again only second to picornaviruses [ 8 ] .
Two additional CoVs associated with outbreaks are the severe acute respiratory syndrome-associated CoV (SARS-CoV) and the recently described Middle East respiratory syndrome-CoV (MERS-CoV) . The SARS outbreak originated in Guangdong Province in China in 2002 and was characterized by a life-threatening, atypical pneumonia and was spread by close contact with infected humans, mostly to household contacts and health care workers [ 57 ] . SARS-CoV is not currently circulating in the world with the most recent human cases of infection reported in China in 2004 [ 58 ] . MERS-CoV fi rst emerged in the Arabian Peninsula in 2012, and since then travel-associated cases have been found in a number of countries outside the region [ 59 ] . In adults, the fatality rate is estimated to be 40%; in children asymptomatic infection is common but patients with underlying medical conditions are at increased risk [ 60 , 61 ] . There is little data on the incidence of SARS-CoV and MERS-CoV in immunocompromised hosts, although immune suppression is considered a risk factor. SARS-CoV has been described in liver transplant recipients and in patients with myelodysplastic syndrome [ 62 , 63 ] . MERS-CoV has been described in patients on chronic immunosuppression and in renal transplant recipients with a broad range of clinical presentations [ 64 , 65 ] . Other CoVs have been reported to cause pneumonia in children and immunocompromised patients treated for hematologic malignancies [ 66 -68 ] . The role of coronavirus virus infection prior to transplantation is not known.
Clinical Characteristics
Although most CoV infections result in relatively mild upper respiratory tract infection, these viruses have been associated with more severe LRTI (e.g., bronchiolitis and pneumonia) in patients who are immunosuppressed, have asthma, or are premature. In one retrospective study carried out over 1 year, CoV was detected in six immunocompromised children-fi ve with acute lymphocytic leukemia and one renal transplant recipient [ 54 ] . Five patients were febrile at the time coronavirus was present, with fevers lasting 1-7 days. All patients initially presented with rhinorrhea and nasal discharge; two children had cough as a presenting symptom. Chest radiographs of only one of the three children were abnormal; LRTI based on decreased oxygen saturation, tachypnea, and abnormal chest radiograph was present in only one child with leukemia, who was signifi cantly neutropenic and lymphopenic at the time CoV was detected. CoVs have been associated with LRTI in HCT recipients with sometimes fatal outcomes [ 66 , 67 , 69 -71 ] . The clinical characteristics of SARS-CoV and MERS-CoV infection in HCT and SOT patients are not well described, and presentation can range from mild symptoms to respiratory failure and death [ 62 -65 , 72 ].
Diagnosis
Until the advent of RT-PCR , techniques for the detection of CoV were limited and the reliable identifi cation of CoV was problematic. Early detection techniques isolated two subtypes-OC43 and 229E, originally using organ cultures of human embryonic trachea, with morphology determined using negative staining with electron microscopy [ 73 ] . With the advent of molecular detection methods and increased interest in CoV detection during the SARS outbreak, new strains of CoVs have been discovered and new RT-PCR assays developed that facilitate further studies of these viruses. Based on RT-PCR assays, four strains of non-SARS CoVs (OC43, 229E, NL63, and HKU1) appear to cocirculate during the non-summer months in temperate climates, and are associated with symptomatic disease in immunocompromised hosts [ 54 ] . Guidance on RT-PCR and serologic assays for the confi rmation on MERS-CoV can be found on the World Health Organization website [ 74 ] .
Treatment Options
There are no approved antivirals for prophylaxis or treatment of CoV infections and supportive care remains paramount in managing patients infected with coronaviruses. Though several antivirals were used during the SARS-CoV epidemic, no clear benefi t could be established on systematic review [ 75 ] . Oral ribavirin was evaluated in retrospective studies for the treatment of MERS-CoV in immunocompetent individuals; decreased survival was noted in one study when compared to matched controls [ 76 , 77 ] , however, larger prospective studies are needed to show true effi cacy. Shedding of all coronaviruses may persist for up to months, and routine infection control practices are encouraged.
Enteroviruses
Epidemiology
EVs are part of the picornaviridae family of viruses and can be associated with severe illness in immunocompromised hosts. EVs include polioviruses, coxsackieviruses, and echoviruses; these are now all classified into four species: Enterovirus A (EV-A), EV-B, EV-C, and EV-D. Risk for infection and subsequent poor outcomes appears to be heavily influenced by age, although factors such as sex and socioeconomic status play a role in the general population. EV activity can be either sporadic or epidemic, and several outbreaks have been described. EVs are typically found during the summer and early autumn in temperate climates.
Enterovirus-D68 (EV-D68) was fi rst identifi ed in California in 1962 [ 78 ] and has since been associated with several small outbreaks, both in the US and internationally, from 2009 to 2013 [ 79 -84 ] . In the summer of 2014, several hundred cases of severe respiratory illnesses in children in the United States were found to be associated with EV-D68 infection [ 85 ] , and several additional clusters have been described worldwide [ 86 -96 ] .
Clinical Characteristics
EVs can cause a wide spectrum of illnesses in immunocompetent individuals including asymptomatic infection, poliomyelitis, meningitis, encephalitis, cardiac disease, muscle disease, eye infections, respiratory infections, exanthems, and neonatal disease. The most frequently described manifestation in immunocompromised patients is respiratory disease, although the incidence and spectrum of disease is not known. According to one study, EVs can be associated with lower respiratory tract infection and mortality; however, larger studies are needed to establish specifi c risk factors for worse outcomes [ 97 ] .
Most confi rmed cases of EV-D68 infection have been in children, occurring primarily in patients with underlying lung disease such as asthma or a history of wheezing. EV-D68 was also associated with several cases of acute fl accid paralysis in children during the 2014 outbreak in the United States, although defi nitive causation has not yet been established [ 98 , 99 ] . The impact of EV-D68 infection in immunocompromised hosts is not known; however, the association between EV-D68 and severe illness was described in eight adult immunocompromised patients with presumptive EV-D68 infection including HCT recipients [ 100 ] . Additionally, one recent report of adults with confi rmed EV-D68 infection included solid organ transplant recipients [ 87 ] .
Diagnosis
Depending on the clinical scenario, EVs can be detected from a number of clinical specimens including cerebral spinal fl uid, serum, respiratory specimens, cardiac tissue, and stool. EVs may be identifi ed in throat samples as well as fecal specimens and cerebrospinal fl uid. Commercial multiplex PCR assays contain primer/probe sets that may cross react between rhinoviruses and enteroviruses. A specifi c EV-D68 RT-PCR has been developed by the CDC and has been made publically available [ 101 ].
Treatment Options
There are no approved antivirals approved for the treatment of EVs. Intravenous immunoglobulin (IVIG) has been used in the treatment of neonatal enteroviral sepsis, but the effect on clinical outcomes is highly dependent on the presence of specifi c neutralizing antibodies and timing of administration [ 102 , 103 ] . Pleconaril , an oral capsid inhibitor with activity against picornaviruses, has been evaluated in treatment of enteroviral infections including meningitis, neonatal sepsis, and respiratory infections [ 104 -108 ] but is not available for treatment. Other capsid binders, protease inhibitors, and polymerase inhibitors are in various stages of development, but none are currently available for treatment of enteroviral infections [ 109 ] . No studies have shown effi cacy in immunocompromised hosts.
Bocavirus
Human bocavirus (HBoV) is a newly identifi ed human parvovirus that was originally identifi ed by random PCR amplifi cation/cloning technique on pooled respiratory secretions from hospitalized children with respiratory tract symptoms [ 110 ] . This virus was named "human bocavirus," due to its relatedness to the genome organization of two other parvoviruses, bovine parvovirus and minute virus of canines, in the family Parvoviridae. This virus continues to be detected in young children with a winter seasonality [ 111 -113 ] . The relationship of HBoV and respiratory disease in immunocompromised patients is not yet clear. Preliminary evidence to date demonstrates case reports of disseminated HBoV infection with involvement of the respiratory tract, blood, and stool in several patients, sometimes associated with GVHD and prolonged viral shedding in the feces [ 114 , 115 ] . Other studies have reported little evidence linking this virus with pulmonary pathology or severe respiratory disease in HCT or lung transplant recipients [ 116 -118 ] . Further research is necessary to link this virus with the disease in the transplant recipient. No specifi c antiviral therapy is available.
Future Directions and Unmet Needs
Respiratory viruses are a signifi cant concern following HCT and SOT and can be associated with substantial morbidity and mortality, even among viruses traditionally not concerned pathogenic. New, sensitive diagnostic assays allow for routine detection of rhinoviruses, enteroviruses, coronaviruses, and bocavirus, and additional data on the epidemiology, risk factors, outcomes of infection, and the impact of different viral strains are desperately needed. Preliminary studies suggest that detection of these viruses prior to transplant may affect outcomes, but additional studies are needed to explore this important clinical area. Furthermore, as new antivirals are being developed, it will be important to identify high-risk patients that may benefi t from treatment. Finally, a better understanding of these viruses will be able to inform better infection prevention strategies that will remain the mainstay of viral control.
